SEC Company Response from Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654) (ORKA) — Jan 24, 2012
Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654)
Date: Jan. 24, 2012 · CIK: 0000907654 · Accession: 0001193125-12-021809
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-178984
Referenced dates: January 19, 2012
Letter
Division of Corporation Finance ARCA biopharma, Inc. Amendment No.1 to Registration Statement on Form S-3 Filed January 12, 2012 File Nos. 333-178984
Dear Mr. Riedler, Mr. Krug and Mr. Greenspan:
On behalf of ARCA biopharma, Inc. (the “Company”), enclosed for electronic filing via EDGAR pursuant to the Securities Act of 1933, as amended, is Amendment No. 1 to the Company’s Registration Statement on Form S-3 originally filed with the Securities and Exchange Commission (the “Commission”) on January 12, 2012.
Response to Staff Comments
This letter includes the responses and supplemental information requested by the staff of the Commission (the “Staff”) in a letter dated January 19, 2012 to Dr. Michael Bristow from Mr. Jeffrey Riedler. For your convenience, each of the Staff’s comments has been reprinted in italics below.
Amendment No. 1 reflects changes made in response to the Staff’s comments, as well as limited updating with respect to the filing of this amendment and the final prospectus.
Signature Page
1. Comment: The registration statement should also be signed by the registrant’s controller or principal accounting officer. Any person who occupies more than one of the specified positions required to sign the registration statement should indicate each capacity in which he signs the registration statement. See Instructions to Signatures to Form S-3.
380 INTERLOCKEN CRESCENT, SUITE 900, BROOMFIELD, CO 80021-8023 T: (720) 566-4000 F: (720) 566-4099 WWW.COOLEY.COM
Securities and Exchange Commission
January 24, 2012
Page Two
Response: The Company has revised the signature page as requested to indicate that the Company’s principal financial officer is also its principal accounting officer. The Company has obtained manually executed signature pages from such officer in both such capacities prior to the time of this electronic filing.
Please do not hesitate to contact the undersigned at (720) 566-4025 or Bryn Weaver at (720) 566-4252 if we can be of assistance.
Very truly yours,
COOLEY LLP
Show Raw Text
CORRESP
1
filename1.htm
Correspondence
Brent D. Fassett
T: +1 720 566 4025
fassettbd@cooley.com
January 24, 2012
Division of Corporation Finance
U.S. Securities & Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attn:
Jeffrey Riedler
John Krug
Daniel Greenspan
Re:
ARCA biopharma, Inc.
Amendment No.1 to Registration Statement on Form S-3
Filed January 12, 2012
File Nos. 333-178984
Dear Mr. Riedler, Mr. Krug and Mr. Greenspan:
On behalf of ARCA biopharma, Inc. (the “Company”), enclosed for electronic filing via EDGAR pursuant to the Securities Act of 1933, as amended, is Amendment No. 1 to the
Company’s Registration Statement on Form S-3 originally filed with the Securities and Exchange Commission (the “Commission”) on January 12, 2012.
Response to Staff Comments
This letter includes the responses and supplemental information
requested by the staff of the Commission (the “Staff”) in a letter dated January 19, 2012 to Dr. Michael Bristow from Mr. Jeffrey Riedler. For your convenience, each of the Staff’s comments has been
reprinted in italics below.
Amendment No. 1 reflects changes made in response to the Staff’s comments, as well as limited updating
with respect to the filing of this amendment and the final prospectus.
Signature Page
1. Comment: The registration statement should also be signed by the registrant’s controller or principal accounting officer. Any person who
occupies more than one of the specified positions required to sign the registration statement should indicate each capacity in which he signs the registration statement. See Instructions to Signatures to Form S-3.
380 INTERLOCKEN CRESCENT, SUITE 900, BROOMFIELD, CO 80021-8023 T: (720) 566-4000 F: (720) 566-4099 WWW.COOLEY.COM
Securities and Exchange
Commission
January 24, 2012
Page
Two
Response: The Company has revised the signature page as requested to indicate that
the Company’s principal financial officer is also its principal accounting officer. The Company has obtained manually executed signature pages from such officer in both such capacities prior to the time of this electronic filing.
Please do not hesitate to contact the undersigned at (720) 566-4025 or Bryn Weaver at (720) 566-4252 if we can be of assistance.
Very truly yours,
COOLEY LLP
/s/ Brent D. Fassett
Brent D. Fassett
Enclosure
380 INTERLOCKEN CRESCENT, SUITE 900, BROOMFIELD, CO 80021-8023 T: (720) 566-4000 F:
(720) 566-4099 WWW.COOLEY.COM